Bulletin
Investor Alert
Philip van Doorn

Deep Dive Archives | Email alerts

Feb. 28, 2020, 9:39 a.m. EST

These are the only 7 stocks in the S&P 500 that rose while the market plunged

The company whose stock has risen the most is working on drug trials to fight COVID-19

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    S&P 500 Index (SPX)
  • X
    Tesla Inc. (TSLA)
  • X
    Gilead Sciences Inc. (GILD)

or Cancel Already have a watchlist? Log In

By Philip van Doorn, MarketWatch


Bloomberg News
Gilead Sciences is holding drug trials to see if its Remdesivir medication is effective against the COVID-10 virus.

In any market environment, there are exceptions to the trend. But there aren’t many this time.

Since the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.36%  hit its last closing record on Feb. 19, the index has skidded 12% — and only seven of the component stocks haven’t declined through the close on Feb. 27. See the list below.

Before you get there, here’s a list of stocks in the index that took the worst beatings, along with a summary of how the 11 sectors performed.

It might surprise you that Tesla /zigman2/quotes/203558040/composite TSLA +0.13%  isn’t on that list of decliners, but the electric car maker hasn’t yet met the requirements to be included in the S&P 500. Before the outbreak of the coronavirus strain known as COVID-19, it appeared likely to be added to the index by the end of 2020. Tesla’s stock was down nearly $100 (13%) on Feb. 27 to close at $679. The stock was down $238 (26%) since it set a closing record of $917.42 on Feb. 19.

Read: Tesla’s stock tumbles toward biggest-ever weekly drop

So here are the exceptions — seven S&P 500 stocks that rose in price between Feb. 19 and Feb. 27:

Company Ticker Industry Price change since Feb. 19 Price change - 2020 Decline from 52-week high Price change - 2019
Gilead Sciences Inc. /zigman2/quotes/210293917/composite GILD Biotechnology 7.9% 11.8% -7.9% 3.9%
Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN Biotechnology 7.7% 14.9% -8.2% 0.5%
Clorox Co. /zigman2/quotes/206443229/composite CLX Household/Personal Care 2.3% 9.9% -3.1% -0.4%
E-Trade Financial Corp. /zigman2/quotes/205731930/composite ETFC Investment Banks/Brokers 2.3% 1.3% -19.8% 3.4%
CME Group Inc. Class A /zigman2/quotes/210449693/composite CME Investment Banks/Brokers 1.4% 4.8% -6.6% 6.7%
Newmont Corp. /zigman2/quotes/205356474/composite NEM Precious Metals 0.8% 7.1% -9.4% 25.4%
Cboe Global Markets Inc. /zigman2/quotes/208166986/composite CBOE Investment Banks/Brokers 0.7% 1.0% -5.2% 22.7%
Source: FactSet

You can click the tickers for more about each company.

• Gilead Sciences /zigman2/quotes/210293917/composite GILD -1.18%  has announced two Phase 3 clinical studies to measure the effectiveness of its Remdesivir medication in countering COVID-19 infections. The company’s Feb. 26 press release has more details. Jefferies analyst Michael Yee rates Gilead a “buy,” but wrote in a note to clients on Feb. 26 that although he is pleased that fighting the virus is a ‘very high priority” for Gilead’s management, “the financial implications are modest (pricing, one-time use, no tail).”

• Regeneron Pharmaceuticals /zigman2/quotes/203149337/composite REGN +0.50%  ws upgraded to a “Buy” by Jefferies analyst Biren Amin on Feb. 25, because he believes competitive risk to the company’s Eylea macular degeneration therapy has been minimized because of safety concerns over Novartis AG’s /zigman2/quotes/203243705/composite NVS +0.60%   /zigman2/quotes/203286410/delayed CH:NOVN -0.39%  Beovu medication.

• Clorox /zigman2/quotes/206443229/composite CLX +2.49%  is an obvious defensive stock during a time when people are concerned about the spread of a deadly virus and reaching for bleach. But Charles Lemonides, founder of ValueWorks LLC in New York, argued that for long-term investors, Clorox’s high valuation to earnings actually makes it a risky stock.

• E-Trade Financial /zigman2/quotes/205731930/composite ETFC -0.37%  agreed on Feb. 20 to be acquired by Morgan Stanley /zigman2/quotes/209104354/composite MS -0.40%  in an all-stock deal valued at $58.74 a share at that time. E-Trade’s shares closed at $45.95 Thursday. The deal calls for an exchange of 1.0432 Morgan Stanley shares for every E-Trade share. Morgan Stanley’s shares closed at $45.41 on Feb. 27, so based on those numbers, E-Trade’s takeout price would be $47.37.

<STRONG>Create an email alert for Philip van Doorn’s Deep Dive columns <INTERNAL-PAGE URL="/tools/alerts/newsColumn.asp">here</INTERNAL-PAGE>.</STRONG>

/zigman2/quotes/210599714/realtime
US : S&P US
3,306.51
+11.90 +0.36%
Volume: 2.40B
Aug. 4, 2020 5:20p
loading...
/zigman2/quotes/203558040/composite
US : U.S.: Nasdaq
$ 1,487.00
+2.00 +0.13%
Volume: 8.41M
Aug. 4, 2020 4:00p
P/E Ratio
773.87
Dividend Yield
N/A
Market Cap
$276.75 billion
Rev. per Employee
$439,627
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 70.88
-0.85 -1.18%
Volume: 9.79M
Aug. 4, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
3.84%
Market Cap
$89.98 billion
Rev. per Employee
$2.02M
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 648.43
+3.25 +0.50%
Volume: 747,927
Aug. 4, 2020 4:00p
P/E Ratio
32.59
Dividend Yield
N/A
Market Cap
$72.60 billion
Rev. per Employee
$906,865
loading...
/zigman2/quotes/206443229/composite
US : U.S.: NYSE
$ 237.74
+5.78 +2.49%
Volume: 2.00M
Aug. 4, 2020 4:00p
P/E Ratio
32.33
Dividend Yield
1.87%
Market Cap
$29.02 billion
Rev. per Employee
$717,701
loading...
/zigman2/quotes/205731930/composite
US : U.S.: Nasdaq
$ 51.27
-0.19 -0.37%
Volume: 1.33M
Aug. 4, 2020 4:00p
P/E Ratio
14.90
Dividend Yield
1.09%
Market Cap
$11.38 billion
Rev. per Employee
$761,500
loading...
/zigman2/quotes/210449693/composite
US : U.S.: Nasdaq
$ 163.13
+0.13 +0.08%
Volume: 1.84M
Aug. 4, 2020 4:00p
P/E Ratio
24.63
Dividend Yield
2.08%
Market Cap
$58.45 billion
Rev. per Employee
$960,349
loading...
/zigman2/quotes/205356474/composite
US : U.S.: NYSE
$ 70.25
+2.10 +3.08%
Volume: 7.63M
Aug. 4, 2020 4:00p
P/E Ratio
14.69
Dividend Yield
1.42%
Market Cap
$54.73 billion
Rev. per Employee
$300,083
loading...
/zigman2/quotes/208166986/composite
US : U.S.: Cboe BZX
$ 85.58
-0.75 -0.87%
Volume: 872,425
Aug. 4, 2020 4:00p
P/E Ratio
20.52
Dividend Yield
1.68%
Market Cap
$9.39 billion
Rev. per Employee
$3.29M
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 70.88
-0.85 -1.18%
Volume: 9.79M
Aug. 4, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
3.84%
Market Cap
$89.98 billion
Rev. per Employee
$2.02M
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 648.43
+3.25 +0.50%
Volume: 747,927
Aug. 4, 2020 4:00p
P/E Ratio
32.59
Dividend Yield
N/A
Market Cap
$72.60 billion
Rev. per Employee
$906,865
loading...
/zigman2/quotes/203243705/composite
US : U.S.: NYSE
$ 84.15
+0.50 +0.60%
Volume: 2.12M
Aug. 4, 2020 4:00p
P/E Ratio
26.77
Dividend Yield
2.39%
Market Cap
$185.20 billion
Rev. per Employee
$415,614
loading...
/zigman2/quotes/203286410/delayed
CH : Switzerland: SWX
CHF 77.09
-0.30 -0.39%
Volume: 6.71M
Aug. 4, 2020 5:31p
P/E Ratio
25.17
Dividend Yield
3.83%
Market Cap
CHF170.62 billion
Rev. per Employee
CHF405,818
loading...
/zigman2/quotes/206443229/composite
US : U.S.: NYSE
$ 237.74
+5.78 +2.49%
Volume: 2.00M
Aug. 4, 2020 4:00p
P/E Ratio
32.33
Dividend Yield
1.87%
Market Cap
$29.02 billion
Rev. per Employee
$717,701
loading...
/zigman2/quotes/205731930/composite
US : U.S.: Nasdaq
$ 51.27
-0.19 -0.37%
Volume: 1.33M
Aug. 4, 2020 4:00p
P/E Ratio
14.90
Dividend Yield
1.09%
Market Cap
$11.38 billion
Rev. per Employee
$761,500
loading...
/zigman2/quotes/209104354/composite
US : U.S.: NYSE
$ 49.26
-0.20 -0.40%
Volume: 6.35M
Aug. 4, 2020 4:02p
P/E Ratio
8.89
Dividend Yield
2.84%
Market Cap
$77.93 billion
Rev. per Employee
$831,709
loading...

Philip van Doorn covers various investment and industry topics. He has previously worked as a senior analyst at TheStreet.com. He also has experience in community banking and as a credit analyst at the Federal Home Loan Bank of New York.

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

World News from MarketWatch

Link to MarketWatch's Slice.